Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk348) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML). Issue 3 (March 2015)

• Record Type: Journal Article
• Authors: Bourgne, Céline; Janel, Alexandre; Berger, Juliette; Rapatel, Chantal; Tournilhac, Olivier; Hermet, Eric; Guerci, Agnès; Lioret, Frédérique; Briançon, Aurélie; Bamdad, Mahchid; Boiret-Dupré, Nathalie; Berger, Marc G.
• Is Part Of: Leukemia research. Volume 39:Issue 3(2015:Mar.)
• Page Start: 329
• Page End: 334
• Publication Date: 2015-03
• Subjects: Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2014.11.014
• Languages: English
• ISSNs: 0145-2126

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Over-expression of Syk mRNA in blast cells from BP-CML but not in CP-CML.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Constitutive phosphorylation of Syk Y348 in blast cells from BP-CML but not in CP-CML.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Recurrence of pSyk³⁴⁸ throughout blast cell escape, despite storage of dasatinib.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Combination of dasatinib and R406 did not improve therapeutic efficacy <italic>in vitro</italic>.</p> </list-item> <list-item id="lsti0025"> <label></label> <p id="par0025">Syk activation could be a relevant biomarker of CML disease progression.</p> </list-item> </list> </p> </sec> </abstract>